Monoclonal antibodies targeting amyloid provide small benefits on cognitive and functional scales, which do not meet the minimal clinically important difference.
Myloid-reducing monoclonal antibodies for patients with Alzheimer have harmful risks, such as cerebral edema, hemorrhage, serious adverse events, and death, according to a new study.
Positive Trending Data from 57 Per-Protocol Patients Suggest NE3107 is Biologically Active and May Have Impact on Cognitive, Functional, and Biomarker.